{"classes":[{"categories":[{"measurements":[{"comment":"Not enough events occurred for upper limit calculation","groupId":"OG000","lowerLimit":"2.6","upperLimit":"NA","value":"6.9"},{"comment":"Not enough events occurred for upper limit calculation","groupId":"OG003","lowerLimit":"2.6","upperLimit":"NA","value":"5.9"},{"comment":"Not enough events occurred for median or upper limit calculation","groupId":"OG004","lowerLimit":"10.7","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"13"}],"units":"Participants"}],"description":"The distribution of duration of response will be estimated using the method of Kaplan-Meier. Duration of response (DR) is defined for all evaluable patients who have achieved a PR, nPR, CCR, CRi, or CR (Arms A and B) or PMR, CMR, PR or CR (Arm C) as the date at which the patient's objective status is first noted to be a PR, nPR, CCR, CRi, or CR (Arms A and B) or PMR, CMR, PR or CR (Arm C) to the earliest date relapse is documented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients on Arm A or Arm C experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.","id":"OG000","title":"Arm A (CLL)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG001","title":"Arm B (NHL)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients on Arm A or Arm C experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.","id":"OG002","title":"Arm C (CLL With Richters)"},{"description":"CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG003","title":"Arm A (Continuation Phase)"},{"description":"CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG004","title":"Arm C (Continuation Phase)"}],"paramType":"MEDIAN","populationDescription":"Only patients that achieved a response were used in this analysis","reportingStatus":"POSTED","timeFrame":"5 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}